Evidence map›Paper›PMID 28722124›Full record

ArticleThe Journal of pathology2017

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma.

Claudio Luchini, Antonio Pea, Gemma Lionheart, Andrea Mafficini, Alessia Nottegar, Nicola Veronese, Peter Chianchiano, Lodewijk Aa Brosens, Michaël Noë, G Johan A Offerhaus and 10 more

Abstract read
In one paragraph

Article in The Journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.ORCID 0000-0003-4901-4908
Antonio PeaDepartment of Surgery, University and Hospital Trust of Verona, Verona, Italy.
Gemma LionheartDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrea MafficiniARC-Net Research Center, University of Verona, Verona, Italy.
Alessia NottegarDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Nicola VeroneseNational Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
Peter ChianchianoDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lodewijk Aa BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Michaël NoëDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
G Johan A OfferhausDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Raluca YonescuDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yi NingDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Giuseppe MalleoDepartment of Surgery, University and Hospital Trust of Verona, Verona, Italy.
Giulio RivaDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Paola PiccoliDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Ivana CataldoDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Paola CapelliDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Giuseppe ZamboniDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Laura D WoodDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3096-652X
University of Verona · ITJohns Hopkins University · USFoundation for Cardiovascular Biomedical Research and Gene and Cell Therapy · ITRadboud University Nijmegen · NLUniversity Medical Center Utrecht · NL

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI VOGELSTEIN, BERT · 1993 to 2022
$54.6M
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor LesionsK08DK107781 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WOOD, LAURA DELONG · 2016 to 2020
$846k
NCI NIH HHS P50 CA062924NIDDK NIH HHS K08 DK107781
6 · The paper itself

Abstract

Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCOGC) is currently considered a morphologically and clinically distinct variant of pancreatic ductal adenocarcinoma (PDAC). In this study, we report clinical and pathological features of a series of 22 UCOGCs, including the whole exome sequencing of eight UCOGCs. We observed that 60% of the UCOGCs contained a well-defined epithelial component and that patients with pure UCOGC had a significantly better prognosis than did those with an UCOGC with an associated epithelial neoplasm. The genetic alterations in UCOGC are strikingly similar to those known to drive conventional PDAC, including activating mutations in the oncogene KRAS and inactivating mutations in the tumor suppressor genes CDKN2A, TP53, and SMAD4. These results further support the classification of UCOGC as a PDAC variant and suggest that somatic mutations are not the determinants of the unique phenotype of UCOGC. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Indexed as

AgedAged, 80 and overCarcinoma, Pancreatic DuctalExomeFemaleHumansImmunohistochemistryMaleMiddle AgedMutationNeoplasm ProteinsOsteoclastsPancreatic NeoplasmsNeoplasm ProteinsPDAC variantsundifferentiated carcinoma with osteoclast-like giant cellswhole exome sequencing

Identifiers

PMID28722124
PMCPMC6664430
OpenAlexW2738257057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.